You are here: Home ยป Archives for Curium

Curium schließt Übernahme von Monrol im Rahmen seines Plans zur erheblichen Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im Bereich der Positronen-Emissions-Tomographie (PET) ab

  • Dies positioniert Curium als führenden Hersteller des Isotops Lu–177
  • Integration innovativer F&E–Expertise und Pipeline für Curium
  • Verbesserung der geografischen Abdeckung und Lieferkette von Curium für SPECT und PET

PARIS, March 29, 2025 (GLOBE NEWSWIRE) — Curium Pharma („Curium“), ein weltweit führendes Unternehmen im Bereich der Nuklearmedizin, freut sich, den Abschluss der Übernahme von Eczacıbaşı–Monrol Nuclear Products Co. (Monrol), einem führenden Unternehmen in der Nuklearmedizin mit Sitz in Istanbul, Türkei, bekanntzugeben.

Die Übernahme erhöht die Produktionskapazität von Curium für Lutetium–177 (Lu–177), um die weltweit steigende Nachfrage nach Isotopen zu decken und die Versorgung für die zukünftige Markteinführung der Lu–177–Arzneimittelkandidaten von Curium für Prostatakrebs (derzeit in der Entwicklung) und neuroendokrine Tumore (Zulassung steht noch aus) sicherzustellen.

Monrol ergänzt und erweitert die umfangreichen Forschungs– und Entwicklungskapazitäten (F&E) von Curium, während das Unternehmen sein Portfolio und seine Pipeline innovativer theranostischer Produkte weiter ausbaut. Curium beabsichtigt, den Ga–68–Generator von Monrol in Zukunft weltweit einzusetzen, vorbehaltlich der behördlichen Genehmigungen.

Darüber hinaus erweitert die komplementäre geografische Präsenz von Monrols PET & SPECT das Angebot von Curium. Mit Abschluss der Transaktion erweitert Curium seine Präsenz im Bereich der Positronen–Emissions–Tomographie (PET) von 34 Standorten in Westeuropa und Asien auf 46, da 12 Monrol–eigene und partnerschaftlich betriebene Standorte in Osteuropa sowie Nordafrika und Nahost hinzukommen. Darüber hinaus erweitert die Fertigungs– und Logistikinfrastruktur von Monrol in Istanbul, Türkei, die vertikal integrierten Produktions– und Vertriebskapazitäten von Curium sofort.

Chaitanya Tatineni, CEO International Markets von Curium, kommentierte dies wie folgt: „Wir freuen uns, fast 400 hochqualifizierte und engagierte neue Kollegen in der Curium Group willkommen zu heißen. Der Zusammenschluss von Curium und Monrol wird unsere Größe, unsere Fähigkeiten und unsere Reichweite in mehreren kritischen Bereichen, insbesondere Lu–177, verändern und zahlreiche neue Möglichkeiten schaffen, unser Angebot an lebensverändernden diagnostischen und therapeutischen Lösungen für Patienten auf der ganzen Welt zu verbessern.“

Aydin Kucuk, General Manager bei Monrol, fügte hinzu: „Wir freuen uns, Curium beizutreten, und haben die Fähigkeiten, die Führungsqualitäten und das Engagement des Unternehmens bei der Entwicklung und Bereitstellung erstklassiger nuklearer Diagnoselösungen und Therapien schon lange bewundert. Wir freuen uns darauf, mit unseren neuen Kollegen bei Curium zusammenzuarbeiten, um auf unseren bisherigen gemeinsamen Erfolgen aufzubauen, indem wir unser Fachwissen, unsere Kenntnisse und unsere Erfahrung mit der globalen Präsenz, dem Produktportfolio und der Innovationsbilanz von Curium verbinden.“

Emin Fadıllıoğlu, CEO von Eczacıbaşı Pharmaceutical and Industrial Investment, dazu: „Wir sind sehr stolz auf unsere Zusammenarbeit mit Monrol und die Veränderungen, die das Unternehmen in den letzten Jahren durchlaufen hat. Heute ist Monrol Teil von Curium, einem weltweit führenden Unternehmen in der Nuklearmedizin. Dies ist ein großartiger Beweis für die Qualität des Unternehmens, und wir glauben, dass es unter der Eigentümerschaft von Curium weiterhin florieren und von einem besseren Zugang zu fortschrittlicher Technologie und einem umfangreichen globalen Netzwerk profitieren wird.“

Weitere Informationen:

[email protected]

oder

Ben Valdimarsson
Reputation Inc
Mobil: +44 (0)788 9805930
E–Mail: bvaldimarsson@reputation–inc.com

Über Curium
Curium ist ein weltweit führendes Unternehmen im Bereich der Nuklearmedizin. Wir entwickeln, produzieren und vertreiben erstklassige radiopharmazeutische Produkte, die Patienten auf der ganzen Welt helfen. Unser bewährtes Erbe, kombiniert mit einem bahnbrechenden Ansatz, ist das Markenzeichen für Innovation, Exzellenz und einen unvergleichlichen Service.

Mithilfe seiner Produktionsstätten in Europa und den Vereinigten Staaten liefert Curium SPECT–, PET– und therapeutische radiopharmazeutische Lösungen für lebensbedrohliche Krankheiten an über 14 Millionen Patienten jährlich. Der Name „Curium“ ehrt das Erbe der Pioniere in der Erforschung radioaktiver Materialien, Marie und Pierre Curie, nach denen das radioaktive Element Curium benannt wurde, und unterstreicht unsere Ausrichtung auf die Nuklearmedizin. Weitere Informationen finden Sie unter www.curiumpharma.com

Über Monrol
Monrol ist ein Unternehmen im Bereich der Nuklearmedizin mit Hauptsitz in Istanbul, das bei der Entwicklung und Herstellung von GMP–konformen Radioisotopen und Radiopharmazeutika führend ist. Monrol vertreibt sein erstklassiges Portfolio an Radiopharmazeutika auf den globalen Märkten. Als CMO und CDMO unterstützt Monrol seine Kunden in der frühen Entwicklungsphase und bietet vollständig integrierte Dienstleistungen für schnell agierende, schlanke, virtuelle Unternehmen, die neue Produktkonzepte in die klinische Erprobung bringen, den Nachweis des Konzepts erbringen und die ersten Studien am Menschen durchführen möchten. Monrol hat sich zum Ziel gesetzt, die Behandlung von Krebspatienten durch ein Portfolio von radiopharmazeutischen Produkten, die in mehr als 60 Ländern weltweit vertrieben werden, zugunsten der Patienten zu verändern und zu verbessern. Weitere Informationen finden Sie unter www.monrol.com.


GLOBENEWSWIRE (Distribution ID 9413278)

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

  • Positions Curium as leading manufacturer of Lu–177 isotope
  • Brings innovative R&D expertise and pipeline to Curium
  • Enhances Curium’s SPECT & PET geographical coverage and supply chain

PARIS, March 28, 2025 (GLOBE NEWSWIRE) — Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı–Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine player, which is headquartered in Istanbul, Turkey.

The acquisition enhances Curium’s manufacturing capacity of Lutetium–177 (Lu–177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu–177 drug candidates, for Prostate Cancer (currently in development) and Neuroendocrine Tumours (pending approval).

Monrol complements and adds to Curium’s extensive research & development (R&D) capabilities as it continues to expand its portfolio and pipeline of innovative theranostic products. Curium intends to deploy Monrol’s Ga–68 generator globally in the future, pending regulatory approvals.

In addition, Monrol’s PET & SPECT complementary geographic footprint further expands Curium’s offering. The completion of the deal expands Curium’s PET footprint of 34 sites in Western Europe and Asia to 46 with the addition of 12 Monrol owned and partnered sites in Eastern Europe and MENA regions. Furthermore, Monrol’s manufacturing and logistics infrastructure in Istanbul, Turkey, immediately adds scale to Curium’s vertically integrated production and distribution capabilities.

Mr. Chaitanya Tatineni, Curium’s CEO International Markets commented: “We are delighted to welcome close to 400 highly–skilled and dedicated new colleagues to Curium Group. The coming together of Curium and Monrol will transform our scale, capabilities and reach across several critical areas, in particular Lu–177, and create multiple new opportunities to enhance our offering of life–changing diagnostic and therapeutic solutions to patients around the world.”

Mr. Aydin Kucuk General Manager at Monrol added: “We are excited to be joining Curium and have long admired the company’s capabilities, leadership and commitment to developing and supplying world–class nuclear diagnostics solutions and therapies. We look forward to working with our new Curium colleagues to build on our joint successes to date by integrating our expertise, knowledge and experience with Curium’s global footprint, product portfolio, and track record of innovation.”

Mr. Emin Fadıllıoğlu, CEO, Eczacıbaşı Pharmaceutical and Industrial Investment, said: “We are very proud of our association with Monrol and its transformation in recent years, which today sees them become part of Curium, a world–leader in nuclear medicine. This is a great reflection of the quality of the business, and we believe they will continue to thrive under the ownership of Curium, benefiting from greater access to advanced technology and an extensive global network.”

For more information:

[email protected]

or

Ben Valdimarsson
Reputation Inc
Mob: +44 (0)788 9805930
Email: bvaldimarsson@reputation–inc.com

About Curium
Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world–class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life–threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com

About Monrol
Headquartered in Istanbul, Monrol is a nuclear medicine company leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals, Monrol distributes its world–class radiopharmaceutical products portfolio in global markets. As both a CMO and CDMO, Monrol provides early development support to customers and offers fully integrated services for nimble, lean, virtual companies taking new product concepts into clinical trials, demonstrating proof of concept, and going into first–in–human studies. Monrol is committed to transform and improve patient journey in cancer treatment through a portfolio of radiopharmaceutical products that it distributes to more than 60 countries around the globe. To learn more, visit www.monrol.com.


GLOBENEWSWIRE (Distribution ID 9412464)

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

  • Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu–PSMA–I&T and 64Cu–PSMA–I&T
  • Builds on long–standing relationship between the two companies
  • In Japan around 90,000 new cases of prostate cancer are diagnosed each year

PARIS, Oct. 01, 2024 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today that it has entered into a strategic partnership with PDRadiopharma Inc, a wholly–owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu–PSMA–I&T and 64Cu–PSMA–I&T. The two agents 177Lu–PSMA–I&T and 64Cu–PSMA–I&T target prostate specific membrane antigen (PSMA) expressed on prostate cancer cells and are being investigated for prostate cancer treatment and diagnostics. Both target tumors with high levels of PSMA expression and thus potentially forming a theranostic (therapeutic & diagnostic) pair.

Under the terms of the partnership, Curium and PDRadiopharma will jointly collaborate on clinical development activities of 177Lu–PSMA–I&T and 64Cu–PSMA–I&T in Japan, with PDRadiopharma leading regulatory filing, manufacturing, commercialization, and distribution activities in Japan. Curium will continue to lead global development of the two agents and support PDRadiopharma through technology transfer to support the set–up of manufacturing lines in Japan – including a high throughput Copper 64 manufacturing line based on Curium’s proprietary technology.

Patrick C. Reid, President & CEO of PeptiDream commented: “Targeted radiopharmaceuticals are rapidly revolutionizing how we both diagnose and treat cancer. At PeptiDream and PDRadiopharma we are focused on expanding our pipeline of these powerful targeted therapies, and we are thrilled to be able to accelerate those efforts by partnering with Curium to bring their highly promising prostate cancer targeting radiopharmaceuticals to patients in Japan.”

Masato Murakami, President of PDRadiopharma & CMO of PeptiDream commented: “We are excited to partner with Curium in the development of 177Lu–PSMA–I&T and 64Cu–PSMA–I&T, highly promising products for both the diagnosis and treatment of PSMA–expressing prostate cancer. We look forward to working with Curium to deliver these much–needed agents to prostate cancer patients in Japan as quickly as possible.”

Chaitanya Tatineni, Curium’s CEO International Markets commented: “As a global innovator in the field of radiopharmaceuticals with a promising late–stage oncology pipeline, Curium is delighted to partner with PDRadiopharma which has more than four decades of experience in Japan. Curium and PDRadiopharma plan to leverage their complementary strengths to accelerate the development of innovative products for the benefit of prostate cancer patients in Japan.”

Prostate cancer continues to be widely prevalent in Japan. Annually, there are approximately 90,000 – 100,000 new cases, with patients with metastatic castration–resistant prostate cancer having an overall survival rate of approximately three years in clinical trial settings, and even shorter in the real–world, and there remains a significant unmet medical need for therapies.

177Lu–PSMA–I&T, a PSMA inhibitor conjugated with the radioisotope Lutetium 177, is currently being tested by Curium in a global pivotal Phase 3 ECLIPSE trial (ClinicalTrials.gov identifier; NCT05204927). ECLIPSE is a multi–center, open–label, randomized clinical trial comparing the safety and efficacy of 177Lu–PSMA–I&T versus hormone therapy in patients with metastatic castration–resistant prostate cancer. The ECLIPSE trial enrolled over 400 patients, across 51 trial sites in the United States and Europe.

64Cu–PSMA–I&T PET is currently being investigated in 2 multicenter Phase 3 trials; SOLAR RECUR testing the diagnostic performance in men with biochemical recurrence of prostate cancer (ClinicalTrials.gov identifier NCT06235099) and SOLAR STAGE testing the diagnostic performance in men with newly diagnosed unfavorable intermediate– to high–risk prostate cancer (ClinicalTrials.gov identifier; NCT06235151). The first in human Phase 1/2 SOLAR trial met the co–primary endpoints of region–level correct localization rate and patient–level correct detection rate in patients with histologically–proven metastatic prostate cancer. PSMA–targeted PET/CT imaging is increasingly emerging as a highly sensitive method for detection of locally recurrent or metastatic lesions in the context of biochemical recurrence and for localization of primary prostate cancer.

Curium and PDRadiopharma have a long–standing relationship in the radiopharmaceutical field.

For more information:

PeptiDream Inc.
Yuko Okimoto, IR & Public Affairs
[email protected]

PDRadiopharma Inc.
Noriko Tanaka, General Affairs
s–info–[email protected]

Curium
Ross Bethell
VP, Head of Global Communications
[email protected]

About PeptiDream Inc.
PeptiDream Inc. (Tokyo Stock Exchange Prime Market 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly–owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly–owned internal programs and globally partnered programs. In its non–radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi–functional peptide conjugates (MPC) across an extensive global network of discovery and development partners.   PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en

About PDRadiopharma
PDRadiopharma, a wholly–owned subsidiary of PeptiDream since 2022, has been providing high–quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field in radiopharmaceuticals, since it started its business in 1968. PDRadiopharma currently markets 21 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit www.pdradiopharma.com/en

About Curium
Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world–class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life–threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com    


GLOBENEWSWIRE (Distribution ID 9249316)